Lipinska J, Kaszkowiak M, Malachowska B, et al. - Researchers conducted the study for analyzing the diagnostic and prognostic utility of survivin [an anti-apoptotic oncoprotein known as a cancer tissue marker] in patients with juvenile idiopathic arthritis (JIA). The research included 70 children with JIA—59 newly diagnosed and 11 biologically treated (46 girls and 17 boys) aged 1.5–18 years and 29 healthy children as a control group, appropriately matched in terms of gender and age. Children with JIA have been divided according to the subtype of the JIA. Oligoarthritis was diagnosed in 65.7% of patients. Survivin level was not significantly linked to disease duration time or treatment with TNF-α inhibitors in DMARD’s non-responders. Findings suggested that survivin should be considered as a joint inflammation biomarker beneficial for the diagnosis of oligo- and polyarticular JIA and possibly not based on TNF-α inhibitors therapy.